Journey Medical Corp: Form 10-Q for the period ended Sep 30, 2024
Filed with the SEC on Nov 12, 2024 and accepted by EDGAR at Nov 12, 2024, 16:06 ET.
Management's discussion and analysis
As filed, 44,248 characters, with its headings, lists and tables. Extracted from the main document; charts and exhibits are in the original on sec.gov.
Special Cautionary Notice Regarding Forward-Looking Statements
Certain matters discussed in this report may constitute forward-looking statements for purposes of the Securities Act of 1933, as amended (the “Securities Act”), and the Securities Exchange Act of 1934, as amended (the “Exchange Act”), and involve known and unknown risks, uncertainties and other factors that may cause our actual results, performance or achievements to be materially different from the future results, performance or achievements expressed or implied by such forward-looking statements. The words “anticipate,” “believe,” “estimate,” “may,” “expect,” “will,” “could,” “project,” “should,” “intend” and similar expressions are generally intended to identify forward-looking statements. Our actual results may differ materially from the results anticipated in or implied by these forward-looking statements due to a variety of factors, including, without limitation:
- the fact that our products and product candidates are subject to time and cost intensive regulation and clinical testing and as a result, may never be successfully developed or commercialized;
- a substantial portion of our sales derive from products that are without patent protection and/or are or may become subject to third-party generic competition, the introduction of new competitor products, or an increase in market share of existing competitor products, any of which could have a significant adverse impact on our operating income;
- we operate in a heavily regulated industry, and we cannot predict the impact that any future legislation or administrative or executive action may have on our operations;
- our revenue is dependent mainly upon sales of our dermatology products and any setback relating to the sale of such products could impair our operating results;
- competition could limit our products’ commercial opportunity and profitability, including competition from manufacturers of generic versions of our products;
- the risk that our products do not achieve broad market acceptance, including by government and third-party payors;
- our reliance third parties for several aspects of our operations;
- our dependence on our ability to identify, develop, and acquire or in-license products and integrate them into our operations, at which we may be unsuccessful;
- the dependence of the success of our business, including our ability to finance our company and generate additional revenue, on the successful commercialization of our recently approved product, Emrosi, and any future product candidates that we may develop, in-license or acquire;
- clinical drug development is very expensive, time consuming, and uncertain and our clinical trials may fail to adequately demonstrate the safety and efficacy of our current or any future product candidates;
- our competitors could develop and commercialize products similar or identical to ours;
- risks related to the protection of our intellectual property and our potential inability to maintain sufficient patent protection for our technology and products;
- our business and operations would suffer in the event of computer system failures, cyber-attacks, or deficiencies in our or our third parties’ cybersecurity;
- the effects of major public health issues, epidemics or pandemics on our product revenues and any future clinical trials;
- our potential need to raise additional capital;
- the substantial doubt expressed about our ability to continue as a going concern;
- Fortress controls a voting majority of our common stock, which could be detrimental to our other shareholders; and
- the risks described in under the section titled “Risk Factors” in our Annual Report on Form 10-K for the year ended December 31, 2023 (the “2023 Form 10-K”).
The forward-looking statements contained in this report reflect our views and assumptions as of the effective date of this report. New risks and uncertainties arise from time to time, and it is impossible for us to predict these events or how they may affect us. Except as required by law, we assume no responsibility for updating any forward-looking statements.
We qualify all of our forward-looking statements by these cautionary statements. In addition, with respect to all of our forward-looking statements, we claim the protection of the safe harbor for forward-looking statements contained in the Private Securities Litigation Reform Act of 1995.
Overview
We are a commercial-stage pharmaceutical company founded in October 2014 that primarily focuses on the selling and marketing of FDA-approved prescription pharmaceutical products for the treatment of dermatological conditions. Our current portfolio includes seven branded and two authorized generic prescription drugs for dermatological conditions that are actively marketed in the U.S. We are managed by experienced life science executives with a track record of creating value for their stakeholders and bringing novel medicines to the market, enabling patients to experience increased quality of life and physicians and other licensed medical professionals to provide better care for their patients. We aim to acquire rights to future products by licensing or otherwise acquiring an ownership interest in, funding the research and development of, and eventually commercializing, the products through our field sales force.
Recent Corporate Highlights
FDA Approval of Emrosi
On November 4, 2024, the U.S. Food and Drug Administration (the “FDA”) approved EmrosiTM (Minocycline Hydrochloride Extended Release Capsules, 40 mg), formerly referred to as DFD-29 (“Emrosi”) for the treatment of inflammatory lesions of rosacea in adults. Emrosi was developed by Journey in collaboration with DRL. Journey is completing the manufacturing of Emrosi for the U.S. market and anticipates initial supply will be available in late first quarter or early second quarter of 2025. Journey intends to commercialize Emrosi in the U.S. with its commercial team.
Critical Accounting Polices and Uses of Estimates
Our discussion and analysis of our financial condition and results of operations are based on our consolidated financial statements, which we have prepared in accordance with accounting principles generally accepted in the United States. Applying these principles requires our judgment in determining the appropriateness of acceptable accounting principles and methods of application in diverse and complex economic activities. The preparation of the accompanying financial statements requires us to make estimates and judgments that affect the reported amounts of revenues, expenses, assets and liabilities, and related disclosure of contingent assets and liabilities. We base our estimates on historical experience and other assumptions that we believe are reasonable under the circumstances. Actual results may differ from these estimates under different assumptions or conditions.
For a discussion of our critical accounting estimates, see the section of the 2023 Form 10-K titled “Management’s Discussion and Analysis of Financial Condition and Results of Operations – Critical Accounting Policies and Use of Estimates.” There were no material changes in our critical accounting estimates or accounting policies from December 31, 2023.
Accounting Pronouncements
During the nine-month period ended September 30, 2024, there were no new accounting pronouncements or updates to recently issued accounting pronouncements disclosed in the 2023 Form 10-K that are expected to materially affect the Company’s present or future financial statements.
Emerging Growth Company and Smaller Reporting Company Status
We are an emerging growth company, as defined in the Jumpstart Our Business Startups Act of 2012 (“JOBS Act”). Under the JOBS Act, emerging growth companies can delay the adoption of new or revised accounting standards issued subsequent to the enactment of the JOBS Act until such time as those standards apply to private companies. Other exemptions and reduced reporting requirements under the JOBS Act for emerging growth companies include presentation of only two years of audited financial statements in our annual reports on Form 10-K, an exemption from the requirement to provide an auditor’s report on internal controls over financial reporting pursuant to Section 404 of the Sarbanes-Oxley Act of 2002, as amended, an exemption from any requirement that may be adopted by the Public Company Accounting Oversight Board regarding mandatory audit firm rotation and less extensive disclosure about our executive compensation arrangements. We have elected to use the extended transition period for complying with new or revised accounting standards that have different effective dates for public and private companies until the earlier of the date that (i) we are no longer an emerging growth company or (ii) we affirmatively and irrevocably opt out of the extended transition period provided in the JOBS Act.
We are also a “smaller reporting company,” meaning that either (i) the market value of our shares held by non-affiliates is less than $250 million or (ii) the market value of our shares held by non-affiliates is less than $700 million and our annual revenue was less than $100 million during the most recently completed fiscal year. We may continue to be a smaller reporting company if either (i) the market value of our shares held by non-affiliates is less than $250 million or (ii) our annual revenue was less than $100 million during the most recently completed fiscal year and the market value of our shares held by non-affiliates is less than $700 million. As a smaller reporting company, we may choose to present only the two most recent fiscal years of audited financial statements in our Annual Report on Form 10-K, we have reduced disclosure obligations regarding executive compensation, and smaller reporting companies are permitted to delay adoption of certain recent accounting pronouncements discussed in Note 2 to our consolidated financial statements in this report on Form 10-Q.
Results of Operations
The following table summarizes our results of operations for the three-month periods ended September 30, 2024 and 2023:
Comparison of the Three-Month Periods Ended September 30, 2024 and 2023
($ in thousands, except per share data)
| Revenue: | | Three-Month Periods Ended September 30, 2024 | | 2023 | | Change $% | | |
|---|---|---|---|---|---|---|---|---|
| Product revenue, net | $14,629 | $15,279 | | $(650) | | -4% | ||
| Other revenue | | — | | 19,260 | | (19,260) | | -100% |
| Total revenue | | 14,629 | | 34,539 | | (19,910) | | -58% |
| | | | | | | | | |
| Operating expenses | | | | | | | ||
| Cost of goods sold – product revenue | 5,285 | 6,429 | | (1,144) | | -18% | ||
| Research and development | 842 | 2,229 | | (1,387) | | -62% | ||
| Selling, general and administrative | 11,396 | 8,636 | | 2,760 | | 32% | ||
| Total operating expenses | 17,523 | 17,294 | | 229 | | 1% | ||
| Income (loss) from operations | (2,894) | 17,245 | | (20,139) | | -117% | ||
| | | | | | | | | |
| Other expense (income) | | | | | | | ||
| Interest income | (188) | (8) | | (180) | | 2250% | ||
| Interest expense | | 758 | | 268 | | 490 | | 183% |
| Foreign exchange transaction losses | | 51 | | 101 | | (50) | | -50% |
| Gain on extinguishment of debt | | (1,125) | | — | | (1,125) | | 100% |
| Total other expense (income) | (504) | 361 | | (865) | | -240% | ||
| Income (loss) before income taxes | (2,390) | 16,884 | | (19,274) | | -114% | ||
| | | | | | | | | |
| Income tax expense | — | 95 | | (95) | | -100% | ||
| Net income (loss) | | $(2,390) | | $16,789 | | (19,179) | | -114% |
Revenues
The following table reflects our net product revenue for the three-month periods ended September 30, 2024 and 2023:
($ in thousands)
| | | Three-Month Periods Ended September 30 2024 | | 2023 | | Change $% | | |
|---|---|---|---|---|---|---|---|---|
| Qbrexza® | | $7,583 | | $5,865 | | $1,718 | | 29% |
| Accutane® | | 3,996 | | 4,882 | | (886) | | -18% |
| Amzeeq® | | 1,542 | | 2,336 | | (794) | | -34% |
| Zilxi® | | 558 | | 681 | | (123) | | -18% |
| Other / legacy | | 950 | | 1,515 | | (565) | | -37% |
| Total net product revenue | | $14,629 | | $15,279 | | $(650) | | -4% |
Total net product revenues decreased by $0.7 million, or 4%, to $14.6 million for the three-month period ended September 30, 2024, from $15.3 million for the three-month period ended September 30, 2023.
Qbrexza® net product revenue increased by $1.7 million, or 29%, to $7.6 million for the three-month period ended September 30, 2024, from $5.9 million for the three-month period ended September 30, 2023. The increase is primarily volume driven, due to our continued marketing efforts and the recent expansion of our access and coverage platforms related to the Qbrexza product.
Accutane® net product revenue decreased by $0.9 million, or 18%, to $4.0 million for the three-month period ended September 30, 2024, from $4.9 million for the three-month period ended September 30, 2023 due to recent market competition.
Amzeeq® and Zilxi® net product revenue combined, decreased by $0.9 million, or 30%, to $2.1 million for the three-month period ended September 30, 2024, from $3.0 million for the three-month period ended September 30, 2023. The decrease is primarily due to a slight decrease in unit sales volume and an increase in coupon rebates as a result of the expansion of our patient coverage options under our overall market access program driving average selling prices lower as compared to the prior year quarter.
Net Revenue from our legacy products decreased by $0.6 million, or 37%, to $0.9 million for the three-month period ended September 30, 2024, from $1.5 million for the three-month period ended September 30, 2023. Targadox® continues to experience erosion due to generic competition and we discontinued selling Ximino® on September 29, 2023.
Other Revenue
($in thousands)
| | | Three-Month Periods Ended September 30, 2024 | | 2023 | | Change $% | | |
|---|---|---|---|---|---|---|---|---|
| Other revenue | | — | 19,260 | | (19,260) | | -100% | |
| Total other revenue | | $— | | $19,260 | | $(19,260) | | -100% |
On August 31, 2023, we entered into a license agreement (the “Maruho Agreement”) with Maruho Co., Ltd., a Japanese company specializing in dermatology (“Maruho”), whereby we granted an exclusive license to Maruho to develop and commercialize Qbrexza® for the treatment of primary axillary hyperhidrosis in South Korea, Taiwan, Hong Kong, Macau, Thailand, Indonesia, Malaysia, Philippines, Singapore, Vietnam, Brunei, Cambodia, Myanmar and Laos (the “Territory”). Under the terms of the Maruho Agreement, Maruho paid us $19.0 million as a non - refundable upfront payment. Maruho is also obligated to make royalty payments to us related to sales of the product in the Territory equal to the corresponding rate payable by us to Dermira under the asset purchase agreement between us and Dermira.
Gross-to-Net Sales Accruals
We record gross-to-net sales accruals for sales returns, coupons, managed care rebates, government rebates, and other allowances (chargebacks, distributor service fees, prompt pay discounts), customary to the pharmaceutical industry.
Gross-to-net sales accruals and the balance in the related allowance accounts for the three-month periods ended September 30, 2024 and 2023, were as follows:
($’s in thousands)
| | | Returns | | Coupons | | Managed Care Rebates | | Other | | Total |
|---|---|---|---|---|---|---|---|---|---|---|
| Balance as of June 30, 2024 | | $3,214 | | $1,764 | | $3,803 | | $1,029 | | $9,810 |
| Current provision related to sales in the current period | | 456 | | 18,241 | | 6,228 | | 1,066 | | 25,991 |
| Checks/credits issued to third parties | | (240) | | (18,289) | | (6,370) | | (1,151) | | (26,050) |
| Balance as of September 30, 2024 | | $3,430 | | $1,716 | | $3,661 | | $944 | | $9,751 |
($’s in thousands)
| | | Returns | | Coupons | | Managed Care Rebates | | Other | | Total |
|---|---|---|---|---|---|---|---|---|---|---|
| Balance as of June 30, 2023 | | $4,545 | | $4,092 | | $3,732 | | $4,753 | | $17,122 |
| Current provision related to sales in the current period | | 497 | | 20,604 | | 5,478 | | 2,247 | | 28,826 |
| Checks/credits issued to third parties | | (519) | | (22,926) | | (6,266) | | (5,572) | | (35,283) |
| Balance as of September 30, 2023 | | $4,523 | | $1,770 | | $2,944 | | $1,428 | | $10,665 |
Gross-to-net sales accruals are primarily a function of product sales volume, mix of products sold, and contractual discounts or rebates. Our reserves for gross-to-net sales allowances were $9.8 million at September 30, 2024, compared to $9.8 million at June 30, 2024, consistent from period-to-period.
Cost of Goods Sold
Cost of goods sold decreased by $1.1 million, or 18%, to $5.3 million for the three-month period ended September 30, 2024, from $6.4 million for the three-month period ended September 30, 2023 driving an increase in our gross product margin of 6.0%, from 57.9% for the three-month period ended September 30, 2023, to 63.9% for the three-month period ended September 30, 2024. The decrease in cost of goods sold and related increase in our gross product margin from period-to-period is mainly due to $0.6 million in inventory charges recorded in the prior year period and a decrease of $0.2 million in product royalties from the same period in 2023, resulting from lower sales of Accutane and the contractual expiration of our Exelderm® product royalty in November 2023. Additionally, Prescription User Drug (PDUFA) fees were lower than the same period in 2023 by $0.3 million, due to the discontinuation of Ximino® in September of 2023. Non-cash amortization of acquired intangible assets was $0.8 million for each of the three-month periods ending September 30, 2024 and 2023.
Research and Development
Research and Development (“R&D”) expenses decreased by $1.4 million, to $0.8 million for the three-month period ended September 30, 2024, from $2.2 million for the three-month period ended September 30, 2023. The decrease is primarily driven by lower clinical trial expenses to develop Emrosi, offset slightly by R&D-related launch costs for the product, as the clinical phase of the project has concluded, and our Emrosi launch efforts have commenced.
Selling, General and Administrative
Selling, general and administrative (“SG&A”) expenses increased by $2.8 million, or 32%, to $11.4 million for the three-month period ended September 30, 2024, from $8.6 million for the three-month period ended September 30, 2023. The increase is mainly due to increases non-cash share-based compensation expense and overall selling and marketing expenses. Non-cash share-based compensation expense increased by $1.0 million as a result of an increase in outstanding equity awards from the same period in 2023. The remaining increase is primarily due to the expansion of our access and coverage platforms and the commencement of our launch efforts for Emrosi related mainly to market research and access and corporate headcount. Additionally, product sample expenses increased from the same period in 2023 due to the timing of delivery of product samples from period-to-period, as the bulk of our product sample expense in 2023 occurred in the first half of the year.
Interest Income
Interest income increased by $0.2 million compared to the same period in 2023. Interest income reflects the income earned on our high yield money market account. The increase is due to a higher invested balance compared to the prior year resulting from entering into the SWK Credit Facility in December 2023, and to a lesser extent, a slight increase in investment yield.
Interest Expense
Interest expense increased by $0.5 million compared to the same period in 2023. In July 2023, we satisfied all of our outstanding debt obligations with East West Bank (“EWB”) by voluntarily repaying the outstanding balance on our term loan under the Loan and Security Agreement with EWB. As such, we had no additional debt or borrowing of funds until entering into the Credit Facility with SWK in December of 2023.
Comparison of the Nine-Month Periods Ended September 30, 2024 and 2023
($in thousands, except per share data)
| Revenue: | | Nine-Month Periods Ended September 30, 2024 | | 2023 | | Change $% | | |
|---|---|---|---|---|---|---|---|---|
| Product revenue, net | | $42,514 | $44,405 | | $(1,891) | | -4% | |
| Other revenue | | — | 19,519 | | (19,519) | | -100% | |
| Total revenue | | 42,514 | 63,924 | | (21,410) | | -33% | |
| | | | | | | | | |
| Operating expenses | | | | | | | | |
| Cost of goods sold – product revenue | | 18,642 | | 20,645 | | (2,003) | | -10% |
| Research and development | | 9,639 | 6,036 | | 3,603 | | 60% | |
| Selling, general and administrative | | 30,144 | 34,069 | | (3,925) | | -12% | |
| Loss on impairment of intangible assets | | — | 3,143 | | (3,143) | | -100% | |
| Total operating expenses | | 58,425 | 63,893 | | (5,468) | | -9% | |
| Income (loss) from operations | | (15,911) | 31 | | (15,942) | | -51426% | |
| | | | | | | | | |
| Other expense (income) | | | | | | | | |
| Interest income | | (566) | (209) | | (357) | | 171% | |
| Interest expense | | 1,869 | 1,674 | | 195 | | 12% | |
| Foreign exchange transaction losses | | 104 | 181 | | (77) | | -43% | |
| Gain on extinguishment of debt | | (1,125) | | — | | (1,125) | | 100% |
| Total other expense (income) | | 282 | 1,646 | | (1,364) | | -83% | |
| Loss before income taxes | | (16,193) | (1,615) | | (14,578) | | 903% | |
| | | | | | | | | |
| Income tax expense | | — | | 95 | | (95) | | -100% |
| Net loss | | $(16,193) | $(1,710) | | (14,483) | | 847% |
Revenues
The following table reflects our net product revenue for the nine-month periods ended September 30, 2024 and 2023:
($in thousands)
| | | Nine-Month Periods Ended September 30 2024 | | 2023 | | Change $% | | |
|---|---|---|---|---|---|---|---|---|
| Qbrexza® | | $19,435 | | $18,038 | | $1,397 | | 8% |
| Accutane® | | 15,534 | | 15,109 | | 425 | | 3% |
| Amzeeq® | | 3,503 | | 4,904 | | (1,401) | | -29% |
| Zilxi® | | 1,200 | | 1,567 | | (367) | | -23% |
| Other / legacy | | 2,842 | | 4,787 | | (1,945) | | -41% |
| Total net product revenue | | $42,514 | | $44,405 | | $(1,891) | | -4% |
Total net product revenues decreased by $1.9 million, or 4%, to $42.5 million for the nine-month period ended September 30, 2024, from $44.4 million for the nine-month period ended September 30, 2023.
Qbrexza® net product revenue increased by $1.4 million, or 8%, to $19.4 million for the nine-month period ended September 30, 2024, from $18.0 million for the nine-month period ended September 30, 2023. The increase is due to an increase in unit sales volume driven by our continued marketing efforts and the expansion of our access and coverage platforms related to Qbrexza.
Accutane net product revenue increased by $0.4 million, or 3%, to $15.5 million for the nine-month period ended September 30, 2024, from $15.1 million for the nine-month period ended September 30, 2023 due to increased unit volume from the expansion of our customer and distribution base as a result of our focused selling and marketing efforts for Accutane.
Amzeeq and Zilxi combined net product revenue decreased by $1.8 million, or 27%, to $4.7 million for the nine-month period ended September 30, 2024, from $6.5 million for the nine-month period ended September 30, 2023. The decrease is substantially due to decreased unit sales volume. In addition, coupon rebates were higher as a result of the expansion of coverage options under our overall market access program. Additionally, managed care rebates increased from the same period in 2023 due to higher managed care utilization and cost increases, driving Amzeeq and Zilxi’s average selling price lower than the prior year.
Net revenue from our legacy products decreased by $1.9 million, or 41%, to $2.8 million for the nine-month period ended September 30, 2024, from $4.8 million for the nine-month period ended September 30, 2023 due to the continued price erosion of Targadox from generic competition, and the discontinuation of Ximino on September 29, 2023.
Other revenue
($in thousands)
| | | Nine-Month Periods Ended September 30, 2024 | | 2023 | | Change $% | | |
|---|---|---|---|---|---|---|---|---|
| Other revenue | | — | 19,519 | | (19,519) | | -100% | |
| Total other revenue | | $— | | $19,519 | | $(19,519) | | -100% |
On August 31, 2023, we entered into the Maruho Agreement where Maruho paid us $19.0 million as a non-refundable upfront payment.
Gross-to-Net Sales Accruals
Gross-to-net sales accruals and the balance in the related allowance accounts for the nine-month periods ended September 30, 2024 and 2023, were as follows:
($’s in thousands)
| | | Returns | | Coupons | | Managed Care Rebates | | Other | | Total |
|---|---|---|---|---|---|---|---|---|---|---|
| Balance as of December 31, 2023 | | $4,077 | | $3,444 | | $5,210 | | $1,386 | | $14,117 |
| Current provision related to sales in the current period | | 1,696 | | 60,556 | | 17,441 | | 4,780 | | 84,473 |
| Checks/credits issued to third parties | | (2,343) | | (62,284) | | (18,990) | | (5,222) | | (88,839) |
| Balance as of September 30, 2024 | | $3,430 | | $1,716 | | $3,661 | | $944 | | $9,751 |
($’s in thousands)
| | | Returns | | Coupons | | Managed Care Rebates | | Other | | Total |
|---|---|---|---|---|---|---|---|---|---|---|
| Balance as of December 31, 2022 | | $3,689 | | $1,696 | | $3,594 | | $2,399 | | $11,378 |
| Current provision related to sales in the current period | | 4,670 | | 74,298 | | 16,892 | | 11,405 | | 107,265 |
| Checks/credits issued to third parties | | (3,836) | | (80,391) | | (17,542) | | (12,376) | | (114,145) |
| Reclass coupon vendor deposit to accounts payable | | — | | 6,167 | | — | | — | | 6,167 |
| Balance as of September 30, 2023 | | $4,523 | | $1,770 | | $2,944 | | $1,428 | | $10,665 |
Our reserves for gross-to-net sales allowances were $9.8 million at September 30, 2024, compared to $14.1 million at December 31, 2023, a decrease of $4.4 million. The decrease in the returns reserve reflects lower units on hand in the wholesaler channel. The decrease in the coupon and managed care reserves is primarily a result of the timing of credits and invoices received at the end of 2023, leading to a higher reserves at December 31, 2023.
Cost of Goods Sold
Cost of goods sold (“COGS”) decreased by $2.0 million, or 10%, to $18.6 million for the nine-month period ended September 30, 2024, from $20.6 million for the nine-month period ended September 30, 2023. Product royalties were lower by $1.0 million compared to the same period in 2023 due to the contractual expiration of our Exelderm product royalty in November 2023, the contractual decrease in our Qbrexza royalty in the second quarter of 2023, and the discontinuation of Ximino in September of 2023. In addition, the discontinuation of Ximo has resulted in lower PDUFA fees of $0.8 million and lower non-cash license amortization of $0.5 million. These decreases were offset, in part, by an increase in product COGS of $0.5 million, as a result of product mix, mainly driven by the higher Accutane net product revenue from period-to-period.
Research and Development
R&D expense increased by $3.6 million, to $9.6 million for the nine-month period ended September 30, 2024, from $6.0 million for the nine-month period ended September 30, 2023. The increase is driven by the $4.1 million filing fee payment to the FDA for Emrosi in January 2024 and a $3.0 million payment for the contractual milestone payment owed to Dr. Reddy’s Laboratories, Ltd (“DRL”) triggered by the FDA’s acceptance of the NDA for Emrosi in March 2024. In addition, Emrosi launch related expenses were an incremental $0.8 million from the same period in 2023 as a result of the commencement of our product launch efforts in 2024. These increases were offset, in part, by $4.3 million of lower clinical trial expenses to develop Emrosi compared to the same period in 2023, as the clinical phase of the project has concluded.
Selling, General and Administrative
SG&A expenses decreased by $3.9 million, or 12%, to $30.1 million for the nine-month period ended September 30, 2024, from $34.1 million for the nine-month period ended September 30, 2023. The decrease is due to our continued expense management efforts, offset by non-cash share-based compensation, the expansion of our access and coverage platforms and the commencement of our launch efforts for Emrosi. SG&A related to our continued expense management efforts, primarily in sales and marketing and other SG&A areas, decreased by $7.6 million compared to the same period in 2023. This decrease is partially offset by a $1.4 million increase in SG&A expenses from period-to-period due to the expansion of our access and coverage platforms, and the commencement of our launch efforts for Emrosi related mainly to market research and access and corporate headcount. In addition, non-cash share-based compensation expense increased by $2.3 million compared to the same period in 2023 as a result of an increase in outstanding equity awards from period-to-period.
Interest Income
Interest income increased by $0.4 million compared to the same period in 2023. Interest income reflects the income earned on our high yield money market account. The increase is due to a higher invested balance compared to the prior year resulting from entering into the SWK Credit Facility in December 2023, and to a lesser extent, a slight increase in investment yield.
Interest Expense
Interest expense increased by $0.2 million compared to the same period in 2023. In July 2023, we satisfied all of our outstanding debt obligations with EWB by voluntarily repaying the outstanding balance on our term loan under the Loan and Security Agreement with EWB. As such, we had no additional debt or borrowing of funds, and therefore incurred only minimal interest expense until entering into the Credit Facility with SWK in December of 2023.
Liquidity and Capital Resources
At September 30, 2024, we had $22.5 million in cash and cash equivalents as compared to $27.4 million of cash and cash equivalents at December 31, 2023.
On December 27, 2023, we entered into a Credit Agreement (the “Credit Agreement”) with SWK Funding LLC (“SWK”). The Credit Agreement originally provided for a term loan facility (the “Credit Facility”) in the original principal amount of up to $20.0 million. On the closing date, we drew $15.0 million. On June 26, 2024, we drew the then remaining $5.0 million under the Credit Facility. Loans under the Credit Facility (the “Term Loans”) mature on December 27, 2027, and bear interest at a rate per annum equal to the three-month term Secured Overnight Financing Rate (“SOFR”) (subject to a SOFR floor of 5%) plus 7.75%. The interest rate resets quarterly. Interest payments began in February 2024 and are paid quarterly. Beginning in February 2026, we are required to repay a portion of the outstanding principal of the Term Loans quarterly in an amount equal to 7.5% of the principal amount of funded Term Loans. The SWK Credit Facility also includes both revenue and liquidity covenants, restrictions as to payment of dividends, and is secured by substantially all assets of the Company. As of June 30, 2023, and as of the date of this Quarterly Report on Form 10-Q, the Company was in compliance with the financial covenants under the SWK Credit Facility.
On July 9, 2024, we entered into an amendment (the “Amendment”) to the Credit Agreement. The Amendment increased the original principal amount of the Credit Facility from $20.0 million to $25.0 million. The $5.0 million of additional principal added in the Amendment is contractually required to be drawn upon FDA approval of Emrosi, subject to receiving approval on or before June 30, 2025. The approval of Emrosi by the FDA triggered the requirement to draw on the remaining $5.0 million under the Credit Facility. As of the date of issuance of these financial statements, we have not drawn on this amount. The FDA approval also triggered a $15.0 million milestone payment obligation to DRL that is due 30 days after the FDA approval. (See Note 19, to the consolidated financial statements, “Subsequent Events”, for further information regarding current contingent regulatory milestone payments to DRL pursuant to the DFD – 29 Agreement).
On December 30, 2022, we filed a shelf registration statement on Form S-3 (File No. 333-269079), which was declared effective by the Securities and Exchange Commission (“SEC”) on January 26, 2023. This shelf registration statement covers the offering, issuance and sale of up to an aggregate of $150.0 million of our common stock, preferred stock, debt securities, warrants, and units (the “2022 Shelf”). In connection with the 2022 Shelf, we entered into an At Market Issuance Sales Agreement (the “Sales Agreement”) relating to shares of our common stock. We may offer and sell up to 4,900,000 shares of our common stock, from time to time, under the Sales Agreement. During the nine months ended September 30, 2024, we issued and sold 325,019 shares of common stock under the 2022 Shelf, generating net proceeds of $1.7 million. At September 30, 2024, 3,826,278 shares remain available for issuance under the 2022 Shelf.
On September 19, 2024, the United Stated District Court Southern District of New York through the United States Marshalls notified us that it has recovered and will be returning to the Company a portion of the misappropriated cash in connection with the previously disclosed September 2021 cybersecurity incident.
We regularly evaluate market conditions, our liquidity profile, and financing alternatives, including out-licensing arrangements for our products to enhance our capital structure. We may seek to raise capital through debt or equity financings to expand our product portfolio and for other strategic initiatives, which may include sales of securities under either the 2022 Shelf or a new registration statement. Additionally, since we received FDA approval for Emrosi on November 4, 2024, we are required to draw on the remaining $5.0 million under the SWK Credit Facility on or before June 30, 2025. We cannot make any assurances that such additional financing will be available and, if available, the terms may negatively impact the Company’s business and operations. Our expectations are based on current assumptions, projected commercial sales of our products, clinical development plans and regulatory submission timelines, which may be uncertain and may not emerge as expected. Additionally, as a result of recurring losses, substantial doubt exists about our ability to continue as a going concern for a period of at least twelve months from the date of issuance of these financial statements.
Cash Flows for the Nine-Month Periods Ended June 30, 2024 and 2023
($’s in thousands)
| | | Nine-Month Periods Ended September 30, 2024 | | 2023 | | Increase (Decrease) |
|---|---|---|---|---|---|---|
| Net cash (used in) provided by operating activities | | $(11,352) | | $21,760 | | $(33,112) |
| Net cash provided by (used in) investing activities | | — | | (5,000) | | 5,000 |
| Net cash provided by (used in) financing activities | | 6,374 | | (24,014) | | 30,388 |
| Net change in cash and cash equivalents | | (4,978) | | (7,254) | | 2,276 |
Operating Activities
Net cash flows used in operating activities for the nine-month period ended September 30, 2024 were $11.4 million compared to $21.8 million of net cash flows provided by operating activities for the nine-month period ended September 30, 2023, reflecting a change of $33.1 million from period-to-period. Cash provided by operating activities for the nine-month period ended September 30, 2023 includes cash received pursuant to the Maruho Agreement, where Maruho paid us $19.0 million as a non-refundable upfront payment. Additionally, in 2024 we made cash payments of $4.1 million related to the filing fee paid to the FDA for Emrosi in January 2024 and $3.0 million for the contractual milestone payment owed DRL triggered by the FDA’s acceptance of the NDA for Emrosi in March 2024. The remainder was driven primarily by the changes in net working capital.
Investing Activities
The nine-month period ended September 30, 2023 reflects the $5.0 million deferred cash payment paid in January 2023 related to the Vyne Product Acquisition.
Financing Activities
Net cash flows provided by financing activities for the nine-month period ended September 30, 2024 were $6.4 million compared to $24.0 million of net cash flows used in financing activities for the nine-month period ended September 30, 2023, reflecting a change of $30.4 million from period-to-period. Cash provided by financing activities for the nine-month period ended September 30, 2024 reflects the draw of an additional $5.0 million under the SWK Credit Facility in June of 2024, as well as the net proceeds from issuances of common stock under the Sales Agreement of $1.7 million as compared to the paydown of our prior letter of credit and debt facility in the prior year period. Net cash used in financing activities for the nine-month period ended September 30, 2023 reflects the voluntarily repayment the outstanding balance on our term loan under the Loan and Security Agreement with EWB.
Material Cash Requirements
In the normal course of business, we enter into contractual obligations that contain cash requirements of which the most significant currently include the following:
- We are required to make regular payments under the SWK Credit Facility. Based on the amount currently outstanding under the SWK facility and current interest rates, and assuming we do not make further draws under the SWK facility, we expect to make the following payments:
($'s in thousands)
| | | Payments by Period Total | | Remainder of 2024 | | 2025 | | 2026 | | 2027 |
|---|---|---|---|---|---|---|---|---|---|---|
| Interest | | $6,971 | | $664 | | $2,634 | | $2,237 | | $1,436 |
| Principal | | 20,000 | | — | | — | | 6,000 | | 14,000 |
| Exit fee | | 1,000 | | — | | — | | — | | 1,000 |
| Total | | $27,971 | | $664 | | $2,634 | | $8,237 | | $16,436 |
- Excluded from the above table is an additional $5.0 million under the SWB Credit Facility that is contractually required to be drawn upon FDA approval of Emrosi, subject to receiving approval on or before June 30, 2025. The approval of Emrosi by the FDA triggered the requirement to draw on the remaining $5.0 million under the Credit Facility.
- Pursuant to the Vyne Product Acquisition Agreement, upon the achievement of net sales milestones with respect to the products purchased in the Vyne Product Acquisition, we are also required to pay contingent consideration consisting of a one-time payment, per product, of $10.0 million and $20.0 million upon each product reaching annual net sales of $100 million and $200 million, respectively. Each required payment must only be paid one time following the first achievement of the applicable annual net sales milestone amount.
- On June 29, 2021, we entered into the DFD-29 Agreement to obtain the global rights for the development and commercialization of Emrosi with DRL. Based on the development and commercialization of Emrosi, additional contingent regulatory and commercial milestone payments totaling up to $140.0 million, which excludes the $15.0 million milestone payment triggered by FDA approval on November 4, 2024, may also become payable. (See Note 19, to the consolidated financial statements, “Subsequent Events”, for further information regarding current contingent regulatory milestone payments to DRL pursuant to the DFD – 29 Agreement). Royalties ranging from ten percent to twenty percent are payable on net sales of the product. In January 2024, we paid a $4.0 million filing fee to the FDA upon filing of an NDA for Emrosi. We made a $3.0 million contractual milestone payment to DRL in April 2024 based on the FDA’s acceptance of our NDA for Emrosi filed in January 2024. On November 4, 2024, we received FDA approval for Emrosi, which triggered a $15.0 million milestone payment obligation to DRL, that is due 30 days after FDA approval.
- In August 2024, we executed a settlement agreement (the “Settlement Agreement”) to settle amounts owed by us to Sun Pharmaceutical Industries, Inc. (“Sun”) pursuant to the Ximino Asset Purchase Agreement. We owed $3.0 million of license
installment payments to Sun associated with the license of Ximino. Pursuant to the Settlement Agreement, we agreed to settle the total outstanding obligation owed to Sun for a total of $1.9 million, payable in three installments: i) $625.0 thousand upon execution of the Settlement Agreement, ii) $625.0 thousand on December 1, 2024, and iii) $625.0 thousand on January 15, 2025.
- We are contractually obligated to make sales-based royalty payments to Dermira (for Qbrexza), Sun Pharmaceutical Industries (for Exelderm) and PuraCap Caribe (for Targadox). Due to the contingent nature of these obligations, the amounts of these payments cannot be reasonably predicted.
Market risk
As filed, 163 characters, with its headings, lists and tables. Extracted from the main document; charts and exhibits are in the original on sec.gov.
We are a smaller reporting company as defined by Rule 12b-2 of the Exchange Act and are not required to provide the information otherwise required under this item.
Controls and procedures
As filed, 1,317 characters, with its headings, lists and tables. Extracted from the main document; charts and exhibits are in the original on sec.gov.
Evaluation of Disclosure Controls and Procedures
Under the supervision and with the participation of our management, including our principal executive officer and principal financial officer, we conducted an evaluation of the effectiveness, as of June 30, 2024, of the design and operation of our disclosure controls and procedures, as such term is defined in Exchange Act Rules 13a-15(e) and 15d-15(e). Based on this evaluation, our principal executive officer and principal financial officer have concluded that, as of such date, our disclosure controls and procedures are effective to ensure that information required to be disclosed by us in our Exchange Act reports is recorded, processed, summarized, and reported within the time periods specified in the SEC’s rules and forms, and that such information is accumulated and communicated to our management, including our principal executive officer and principal financial officer, as appropriate to allow timely decisions regarding required disclosure.
Changes in Internal Control over Financial Reporting
No change in internal control over financial reporting occurred during the most recent quarter with respect to our operations; which materially affected, or is reasonable likely to materially affect, our internal controls over financial reporting.
Risk factors
As filed, 584 characters, with its headings, lists and tables. Extracted from the main document; charts and exhibits are in the original on sec.gov.
We have disclosed under the heading “Risk Factors” in the 2023 Form 10-K a number of risks which may materially affect our business, financial condition or results of operations. You should carefully consider these Risk Factors and other information set forth elsewhere in this Quarterly Report on Form 10-Q. You should be aware that these risk factors and other information may not describe every risk facing our Company. Additional risks and uncertainties not currently known to us may also materially adversely affect our business, financial condition and/or results of operations.
Figures reported in this filing
Standardized line items from the XBRL in this filing, for the period ended 2024-09-30. Comparative periods it repeats are left out.
| Line item | Period | Value | XBRL concept |
|---|---|---|---|
| Revenue | 3 months2024-07-01 to 2024-09-30 | $14.6m | us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax |
| Revenue | 9 months2024-01-01 to 2024-09-30 | $42.5m | us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax |
| Cost of revenue | 3 months2024-07-01 to 2024-09-30 | $5.3m | us-gaap:CostOfRevenue |
| Cost of revenue | 9 months2024-01-01 to 2024-09-30 | $18.6m | us-gaap:CostOfRevenue |
| Research and development | 3 months2024-07-01 to 2024-09-30 | $842.0k | us-gaap:ResearchAndDevelopmentExpense |
| Research and development | 9 months2024-01-01 to 2024-09-30 | $9.6m | us-gaap:ResearchAndDevelopmentExpense |
| Selling, general and administrative | 3 months2024-07-01 to 2024-09-30 | $11.4m | us-gaap:SellingGeneralAndAdministrativeExpense |
| Selling, general and administrative | 9 months2024-01-01 to 2024-09-30 | $30.1m | us-gaap:SellingGeneralAndAdministrativeExpense |
| Operating income | 3 months2024-07-01 to 2024-09-30 | −$2.9m | us-gaap:OperatingIncomeLoss |
| Operating income | 9 months2024-01-01 to 2024-09-30 | −$15.9m | us-gaap:OperatingIncomeLoss |
| Interest expense | 3 months2024-07-01 to 2024-09-30 | $758.0k | us-gaap:InterestExpenseNonoperating |
| Interest expense | 9 months2024-01-01 to 2024-09-30 | $1.9m | us-gaap:InterestExpenseNonoperating |
| Net income | 3 months2024-07-01 to 2024-09-30 | −$2.4m | us-gaap:NetIncomeLoss |
| Net income | 9 months2024-01-01 to 2024-09-30 | −$16.2m | us-gaap:NetIncomeLoss |
| Diluted EPS | 3 months2024-07-01 to 2024-09-30 | −$0.12 | us-gaap:EarningsPerShareDiluted |
| Diluted EPS | 9 months2024-01-01 to 2024-09-30 | −$0.80 | us-gaap:EarningsPerShareDiluted |
| Basic EPS | 3 months2024-07-01 to 2024-09-30 | −$0.12 | us-gaap:EarningsPerShareBasic |
| Basic EPS | 9 months2024-01-01 to 2024-09-30 | −$0.80 | us-gaap:EarningsPerShareBasic |
| Diluted shares (weighted) | 3 months2024-07-01 to 2024-09-30 | 20,537,794 shares | us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding |
| Diluted shares (weighted) | 9 months2024-01-01 to 2024-09-30 | 20,137,942 shares | us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding |
| Operating cash flow | 9 months2024-01-01 to 2024-09-30 | −$11.4m | us-gaap:NetCashProvidedByUsedInOperatingActivities |
| Cash and equivalents | At period end2024-09-30 | $22.5m | us-gaap:CashAndCashEquivalentsAtCarryingValue |
| Current assets | At period end2024-09-30 | $46.2m | us-gaap:AssetsCurrent |
| Total assets | At period end2024-09-30 | $64.0m | us-gaap:Assets |
| Current liabilities | At period end2024-09-30 | $33.3m | us-gaap:LiabilitiesCurrent |
| Total liabilities | At period end2024-09-30 | $53.1m | us-gaap:Liabilities |
| Long-term debt | At period end2024-09-30 | $19.8m | us-gaap:LongTermDebtNoncurrent |
| Shareholders' equity | At period end2024-09-30 | $10.9m | us-gaap:StockholdersEquity |
Source: SEC EDGAR, the filing index for accession 0001410578-24-001877. Last ingested by Listed: Nov 13, 2026, 16:22 ET. Listed shows no prices and gives no investment advice.